PTO/SB/21 (08-03) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Number 10/519,121 Filing Date TRANSMITTAL September 15, 2003 (PCT/US03/29361) **FORM** First Named Inventor Marc K. HELLERSTEIN (to be used for all correspondence after initial filing) Art Unit 1638 Examiner Name C. Collins Attorney Docket Number 6+5 416272003900 Total Number of Pages in This Submission refs ENCLOSURES (Check all that apply) After Allowance Communication Fee Transmittal Form Drawing(s) to Group Appeal Communication to Board of Fee Attached Licensing-related Papers Appeals and Interferences Appeal Communication to Group Amendment/Reply Petition (Appeal Notice, Brief, Reply Brief) Petition to Convert to a After Final Proprietary Information Provisional Application Power of Attorney, Revocation Affidavits/declaration(s) Status Letter Change of Correspondence Address Other Enclosure(s) (please Extension of Time Request Terminal Disclaimer identify below): 1. One copy of 5 Cited **Express Abandonment Request** Request for Refund References Information Disclosure Statement CD, Number of CD(s) w/ Form PTO/SB/08a/b (5 pages) 2. Return Receipt Postcard Certified Copy of Priority Document(s) Remarks Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT MORRISON & FOERSTER LLP (Customer No. 20872) Firm Michael R. Ward - 38,651 Individual name richael Rubrd Signature Date may 24 2006 I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below. Signature: Dated:

(Leah Kjellen)

I hereby certify the this correspondence is being deposited with the U.S. Postal Service as First Class MARAD Envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Patent Docket No. 416272003900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Marc K. HELLERSTEIN

Serial No.: 10/519,121

Filing Date: September 15, 2003 (PCT/US03/29361)

For: METHODS FOR MEASURING RATES OF

REVERSE CHOLESTEROL TRANSPORT

IN VIVO, AS AN INDEX OF ANTI-

ATHEROGENESIS

Examiner: C. E. Collins

Group Art Unit: 1638

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicant submits for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of the non-patent literature documents are submitted herewith, except as noted below. The Examiner is requested to make these documents of record.

Non-patent literature Documents numbered 5, 9, 10, and 11, on the attached Form PTO/SB/08a/b were cited in a Supplementary Partial European Search Report mailed on March 9, 2006, directed to related European application no. 03713429.3, filed February 12, 2003 and have not been previously cited, accordingly copies are submitted herewith. Documents numbered 6, 7, and 8 on the attached Form PTO/SB/08a/b were also cited in the Supplementary Search Report, but were previously cited in an information disclosure statement submitted March 11, 2005, for the

2

OF

Application No. 10/519,121 Filed September 15, 2003 (PCT/US03/29361) Supplemental Information Disclosure Statement

current application, and so, copies of the documents are not submitted herewith. A copy of the Supplementary Search Report is submitted herewith. Since document numbered 10 on the attached Form PTO/SB/08a/b contains an English summary, and the Supplementary Search Report in which it is cited is in English, the requirement for a concise explanation of relevance for non-English language information should be fulfilled.

This Supplemental Information Disclosure Statement is submitted: With the application; accordingly, no fee or separate requirements are required. Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided. Within three months of the application filing date or before mailing of a first Office \boxtimes Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided. П After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance. A fee is required. A check in the amount of is enclosed. A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate. A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due. After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee. A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of __ is enclosed. A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicant would appreciate the Examiner initialing and returning the Form

PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicant petitions for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. **416272003900**.

Dated: May 24, 2006

Respectfully submitted,

By Wichael R. Ward

Registration No.: 38,651

MORRISON & FOERSTER LLP

425 Market Street

San Francisco, California 94105-2482

Telephone: (415) 268-6237 Facsimile: (415) 268-7522



Complete if Known Substitute for form 1449/PTO Application Number 10/519,121 September 15, 2003 Filing Date INFORMATION DISCLOSURE (PCT/US03/29361) STATEMENT BY APPLICANT Marc K. HELLERSTEIN First Named Inventor 1638 Art Unit (Use as many sheets as necessary) C. E. Collins Examiner Name 416272003900 of 2 Attorney Docket Number Sheet 1

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document			
	1.	US-5,167,948	12-01-1992	Wenzel			
	2.	US-6,071,245	06-06-2000	Kohno et al.			
	3.	US-6,329,208	12-11-2001	Jones et al.			
	4.	US-2006/0029549-A1	02-09-2006	Hellerstein			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	٦ [¢]	

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴ Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	5.	GUO, Z.K. et al., (2000) "De novo lipogenesis in adipose tissue of lean and obese women: application of deuterated water and isotope ratio mass spectrometry," International Journal of Obesity, 24: 932-937	
	6.	HELLERSTEIN, Marc K. et al. (1986) "Glycoconjugates as Noninvasive Probes of Intrahepatic Metabolism: Pathways of Glucose Entry into Compartmentalized Hepatic UDP-glucose-Pools during Glycogen Accumulation." Proceedings of the National Academy of Sciences of the United States of America 83, Issue 18: 7044-7048	
	7.	HELLERSTEIN, Marc K. et al. (1997) "Measurement of Hepatic Ra UDP-glucose in Vivo in Rats: Relation to Glycogen Deposition and Labeling Patterns" Am. J. Physiol. 272: E155-E162	
	8.	HELLERSTEIN, Marc K. et al. (1999) "Mass Isotopomer Distribution Analysis at Eight Years: Theoretical, Analytic, and Experimental Considerations. Am. J. Physiol. 276: E1146-E1170	
	9.	HELLERSTEIN, Marc K. (2004) "New stable isotope-mass spectrometric techniques for measuring fluxes through intact metabolic pathways in mammalian systems: introduction of moving pictures into functional genomics and biochemical phenotyping," Metabolic	

Examiner	Date	
Signature	 Considered	

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/519,121	
IN	IFORMATIO	N DI	SCLOSURE	Filing Date	September 15, 2003 (PCT/US03/29361)	
S	STATEMENT BY APPLICANT			First Named Inventor	Marc K. HELLERSTEIN	
	(11	h4		Art Unit	1638	
(Use as many sheets as necessary)				Examiner Name	C. E. Collins	
Sheet	2	of	2	Attorney Docket Number	416272003900	

	Engineering, 6: 85-100	
1	MORSCHES, Bernhard (1976) "Tierexperimentelle Untersuchungen uber die Beziehungen zwischen der Hydroxyprolinausscheidung im Urin und den Hydroxyprolinfraktionen im Serum," Der Hautarzt, 27: 234-242	
1	RAVICHANDRAN, L.V. et al., (June 1991) "In vivo labeling studies on the biosynthesis and degradation of collagen in experimental myocardial infarction," Biochemistry Journal, 24(3): 405-414	
1	Supplementary Partial European Search Report mailed March 9, 2006, for European patent application no. EP 03713429.3, filed February 12, 2003, 6 pages	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.